{"url_path":"/sec/bpth/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1133818/0001663577-26-000156-index.html","accession_number":"0001663577-26-000156","cik":"0001133818","ticker":"BPTH","issuer_name":"BIO-PATH HOLDINGS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1133818/0001663577-26-000156-index.html","primary_entity_key":"0001133818","primary_entity_name":"BIO-PATH HOLDINGS, INC."},"word_count":1626,"has_tables":true,"body_markdown":"Bio-Path Holdings, Inc. - Form 10-Q - March 31, 2026\n\nfalse\n2026\nQ1\n--12-31\n0001133818\n\n150\n22\n\n0001133818\n\n2026-01-01\n2026-03-31\n\n0001133818\n\n2026-05-20\n\n0001133818\n\n2026-03-31\n\n0001133818\n\n2025-12-31\n\n0001133818\n\n2025-01-01\n2025-03-31\n\n0001133818\n\n2024-12-31\n\n0001133818\n\n2025-03-31\n\n0001133818\n\nus-gaap:PreferredStockMember\nBPTH:SeriesSPreferredStockMember\n\n2024-12-31\n\n0001133818\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0001133818\n\nBPTH:CommonStockToBeIssuedMember\n\n2024-12-31\n\n0001133818\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0001133818\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0001133818\n\nus-gaap:PreferredStockMember\nBPTH:SeriesSPreferredStockMember\n\n2025-12-31\n\n0001133818\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0001133818\n\nBPTH:CommonStockToBeIssuedMember\n\n2025-12-31\n\n0001133818\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0001133818\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0001133818\n\nus-gaap:PreferredStockMember\nBPTH:SeriesSPreferredStockMember\n\n2025-01-01\n2025-03-31\n\n0001133818\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001133818\n\nBPTH:CommonStockToBeIssuedMember\n\n2025-01-01\n2025-03-31\n\n0001133818\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0001133818\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0001133818\n\nus-gaap:PreferredStockMember\nBPTH:SeriesSPreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001133818\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001133818\n\nBPTH:CommonStockToBeIssuedMember\n\n2026-01-01\n2026-03-31\n\n0001133818\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0001133818\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0001133818\n\nus-gaap:PreferredStockMember\nBPTH:SeriesSPreferredStockMember\n\n2025-03-31\n\n0001133818\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001133818\n\nBPTH:CommonStockToBeIssuedMember\n\n2025-03-31\n\n0001133818\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0001133818\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0001133818\n\nus-gaap:PreferredStockMember\nBPTH:SeriesSPreferredStockMember\n\n2026-03-31\n\n0001133818\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001133818\n\nBPTH:CommonStockToBeIssuedMember\n\n2026-03-31\n\n0001133818\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0001133818\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0001133818\n\nBPTH:AccreditedInvestor1800DiagonalLendingMember\n\n2025-03-06\n\n0001133818\n\nBPTH:AccreditedInvestor1800DiagonalLendingMember\n\n2025-03-06\n2025-03-06\n\n0001133818\n\nBPTH:AccreditedInvestor1800DiagonalLendingNote2Member\n\n2025-03-28\n\n0001133818\n\nBPTH:AccreditedInvestor1800DiagonalLendingNote2Member\n\n2025-03-28\n2025-03-28\n\n0001133818\n\nBPTH:AccreditedInvestor1800DiagonalLendingNote3Member\n\n2025-04-28\n\n0001133818\n\nBPTH:AccreditedInvestor1800DiagonalLendingNote3Member\n\n2025-04-28\n2025-04-28\n\n0001133818\n\nBPTH:VanquishFundingGroupMember\n\n2025-12-29\n\n0001133818\n\nBPTH:VanquishFundingGroupMember\n\n2025-12-29\n2025-12-29\n\n0001133818\n\nBPTH:AccreditedInvestorMember\n\n2026-01-02\n\n0001133818\n\nBPTH:AccreditedInvestorMember\n\n2026-01-02\n2026-01-02\n\n0001133818\n\nBPTH:AccreditedInvestor1800DiagonalLendingNotesMember\n\n2026-01-01\n2026-03-31\n\n0001133818\n\nBPTH:AccreditedInvestor1800DiagonalLendingNotesMember\n\n2026-03-31\n\n0001133818\n\nBPTH:SteelGiantAdvisorsMember\n\n2025-10-24\n2025-10-24\n\n0001133818\n\nBPTH:SteelGiantAdvisorsMember\n\n2025-10-24\n\n0001133818\n\nus-gaap:FairValueInputsLevel1Member\n\n2026-03-31\n\n0001133818\n\nus-gaap:FairValueInputsLevel2Member\n\n2026-03-31\n\n0001133818\n\nus-gaap:FairValueInputsLevel3Member\n\n2026-03-31\n\n0001133818\n\nus-gaap:FairValueInputsLevel1Member\n\n2025-12-31\n\n0001133818\n\nus-gaap:FairValueInputsLevel2Member\n\n2025-12-31\n\n0001133818\n\nus-gaap:FairValueInputsLevel3Member\n\n2025-12-31\n\n0001133818\n\nus-gaap:WarrantsAndRightsSubjectToMandatoryRedemptionMember\n\n2026-03-31\n\n0001133818\n\nBPTH:SeriesSPreferredStockMember\n\n2026-03-31\n\n0001133818\n\n2025-07-01\n2025-09-30\n\n0001133818\n\n2024-07-01\n2024-09-30\n\n0001133818\n\nus-gaap:GeneralAndAdministrativeExpenseMember\n\n2025-07-01\n2025-09-30\n\n0001133818\n\nus-gaap:GeneralAndAdministrativeExpenseMember\n\n2024-07-01\n2024-09-30\n\n0001133818\n\nus-gaap:ResearchAndDevelopmentExpenseMember\n\n2026-01-01\n2026-03-31\n\n0001133818\n\nus-gaap:ResearchAndDevelopmentExpenseMember\n\n2025-01-01\n2025-03-31\n\n0001133818\n\nBPTH:DrugSupplierProjectPlanMember\n\n2026-03-31\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure\n\n** **\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n**FORM 10-Q**\n\n** **\n\n**(Mark One)**\n\n☒\nQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE\nACT OF 1934\n\nFor the quarterly period ended March 31, 2026\n\nOr\n\n☐\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE\nACT OF 1934\n\nFor the transition period from __________ to __________\n\nCommission file number: 001-36333\n\n**Bio-Path Holdings, Inc.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n \n \n \n\nDelaware\n \n87-0652870\n\n(State or other jurisdiction of\n \n(I.R.S. Employer\n\nincorporation or organization)\n \nIdentification No.)\n\n \n\n \n \n \n\n625 Stanwix St. #2407, Pittsburgh, Pennsylvania\n \n15222\n\n(Address of principal executive offices)\n \n(Zip Code)\n\n \n\n \n\n \n\n(630) 708-0750\n\n(Registrant’s telephone number, including area code)\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act: None.\n\n \n\nIndicate\nby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities\nExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),\nand (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No☒ \n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405\nof Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant\nwas required to submit such files). Yes ☐ No☒\n\n \n\nby check mark whether the registrant is a large accelerated\nfiler, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions\nof “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging\ngrowth company” in Rule 12b-2 of the Exchange Act.\n\n \n \n \n \n\n \nLarge accelerated filer ☐\nAccelerated filer ☐\n \n\n \nNon-accelerated filer ☒\nSmaller reporting company ☒\n \n\n \n \nEmerging growth company ☐\n \n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\n \n\nAt May 20, 2026, the Company had 50,297,451 outstanding shares\nof common stock, par value $0.001 per share, with a total value of $1,664,846.\n\n \n\n 1 \n\n[Table of Contents](#toc) \n\nUnless the context requires otherwise,\nreferences in this Quarterly Report on Form 10-Q to “we,” “our,” “us,” “the Company” and\n“Bio-Path” refer to Bio-Path Holdings, Inc. and its subsidiary. Bio-Path Holdings, Inc.’s wholly-owned subsidiary,\nBio-Path, Inc., is sometimes referred to herein as “Bio-Path Subsidiary.”\n\n** **\n\n**CAUTIONARY NOTE REGARDING FORWARD-LOOKING\nSTATEMENTS**\n\n \n\nThis Quarterly Report on Form\n10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended\n(the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).\nForward-looking statements can be identified by words such as “anticipate,” “expect,” “intend,” “plan,”\n“believe,” “seek,” “estimate,” “project,” “goal,” “strategy,”\n“future,” “likely,” “may,” “should,” “will” and variations of these words\nand similar references to future periods, although not all forward-looking statements contain these identifying words. Forward-looking\nstatements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations\nand assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy\nand other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties\nand changes in circumstances, including those discussed in “Item 1A. Risk Factors” to Part I of our Annual Report on Form\n10-K for the fiscal year ended December 31, 2024 and in other reports or documents we file with the U.S. Securities and Exchange Commission\n(“SEC”). As a result, our actual results and financial condition may differ materially from those expressed or forecasted\nin the forward-looking statements, and you should not rely on such forward-looking statements. We can give no assurances that any of the\nevents anticipated by the forward-looking statements will occur or, if any of them do, what impact they will have on our results of operations\nand financial condition. Important factors that could cause our actual results and financial condition to differ materially from those\nindicated in the forward-looking statements include, among others, the following:\n\n \n\n \n•\nour lack of significant revenue to date, our history of recurring operating losses and our expectation of future operating losses;\n\n \n\n \n•\nour need for substantial additional capital and our need to delay, reduce or eliminate our drug development and commercialization efforts if we are unable to raise additional capital;\n\n \n\n \n•\nthe highly competitive nature of the pharmaceutical and biotechnology industry and our ability to compete effectively;\n\n \n\n \n•\nthe success of our plans to use collaboration arrangements to leverage our capabilities;\n\n \n\n \n•\nour ability to retain and attract key personnel;\n\n \n\n \n•\nthe risk of misconduct of our employees, agents, consultants and commercial partners;\n\n \n\n \n•\ndisruptions to our operations due to expansions of our operations;\n\n \n\n \n•\nthe costs we would incur if we acquire or license technologies, resources or drug candidates;\n\n \n\n \n•\nrisks associated with product liability claims;\n\n \n\n \n•\nour reliance on information technology systems and the liability or interruption associated with cyber-attacks or other breaches of our systems;\n\n \n\n \n•\nour ability to use net operating loss carryforwards;\n\n \n\n \n•\nprovisions in our charter documents and state law that may prevent a change in control;\n\n \n\n \n•\nwork slowdown or stoppage at government agencies could negatively impact our business;\n\n \n\n \n•\nthe impact, risks and uncertainties related to global pandemics, including the COVID-19 pandemic, and actions taken by governmental authorities or others in connection therewith;\n\n \n\n \n•\nour need to complete extensive clinical trials and the risk that we may not be able to demonstrate the safety and efficacy of our drug candidates;\n\n \n\n \n•\nrisks that our clinical trials may be delayed or terminated;\n\n \n\n \n•\nour ability to obtain domestic and/or foreign regulatory approval for our drug candidates;\n\n \n\n \n•\nchanges in existing laws and regulations affecting the healthcare industry;\n\n \n\n \n•\nour reliance on third parties to conduct clinical trials for our drug candidates;\n\n \n\n \n•\nour ability to maintain orphan drug exclusivity for our drug candidates;\n\n \n\n \n•\nour reliance on third parties for manufacturing our clinical drug supplies;\n\n \n\n \n•\nrisks associated with the manufacture of our drug candidates;\n\n \n\n \n•\nour ability to establish sales and marketing capabilities relating to our drug candidates;\n\n \n\n \n•\nmarket acceptance of our drug candidates;\n\n \n\n \n•\nthird-party payor reimbursement practices;\n\n \n\n \n•\nour ability to adequately protect the intellectual property of our drug candidates;\n\n \n\n \n•\ninfringement on the intellectual property rights of third parties;\n\n \n\n \n•\ncosts and time relating to litigation regarding intellectual property rights;\n\n \n\n \n•\nour ability to adequately prevent disclosure by our employees or others of trade secrets and other proprietary information;\n\n \n\n \n•\nour need to raise additional capital;\n\n \n\n \n•\nthe volatility of the trading price of our common stock;\n\n \n\n \n•\nour common stock being thinly traded;\n\n \n\n \n•\nour ability to issue shares of common or preferred stock without approval from our stockholders;\n\n \n\n \n•\nour ability to pay cash dividends;\n\n \n\n \n•\ncosts and expenses associated with being a public company; and\n\n \n\n \n•\nour ability to maintain effective internal controls over financial reporting.\n\n \n\nPlease also refer to “Item\n1A. Risk Factors” to Part I of our Annual Report on Form 10-K as of the fiscal year ended December 31, 2024, “Item 1A. Risk\nFactors” to Part II of this Quarterly Report on Form 10-Q and other reports or documents we file with the SEC for a discussion of\nrisks and factors that could cause our actual results and financial condition to differ materially from those expressed or forecasted\nin this Quarterly Report on Form 10-Q.\n\n \n\nAny forward-looking statement\nmade by us in this Quarterly Report on Form 10-Q is based only on information currently available to us and speaks only as of the date\non which it is made. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information,\nfuture developments or otherwise. However, you should carefully review the risk factors set forth in other reports or documents we file\nfrom time to time with the SEC.\n\n \n\n 2 \n\n[Table of Contents](#toc) \n\n \n\n**TABLE OF CONTENTS**\n\n \n \n \n\n \n**Page**\n\n[PART I - FINANCIAL INFORMATION](#a_001)\n4"}